SCHEMBL2082467

SCHEMBL2082467

C/C=C(/CC)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
HTR7 P34969 1/20 0.42
PTGS1 P23219 2/20 0.41
PTGS2 P35354 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
TRPA1 O75762 3/20 0.39
NPC1 O15118 2/20 0.39
PTPN1 P18031 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
PTBP1 P26599 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
ABCB11 O95342 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082470 1.00 ESR1 (0.44) ESR1ESR2HTR7PTGS1PTGS2
SCHEMBL12778960 1.00 ESR1 (0.44) ESR1ESR2HTR7PTGS1PTGS2
SCHEMBL9977621 0.82 TRPA1 (0.42) HTR7PTGS1PTGS2CES2CES1
SCHEMBL9977558 0.82 TRPA1 (0.42) HTR7PTGS1PTGS2CES2CES1
SCHEMBL24876319 0.79 SMN1; SMN2 (0.42) ESR1ESR2HTR7PTGS1PTGS2
SCHEMBL29231852 0.79 SMN1; SMN2 (0.42) ESR1ESR2HTR7PTGS1PTGS2
SCHEMBL28150135 0.79 ESR1 (0.39) ESR1ESR2HTR7PTGS1PTGS2
SCHEMBL6264609 0.79 ESR1 (0.67) ESR1ESR2PTGS1PTGS2GAA
SCHEMBL19159318 0.79 ESR1 (0.45) ESR1ESR2PTGS1CES2CES1
SCHEMBL10581272 0.79 ESR1 (0.67) ESR1ESR2PTGS1PTGS2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897789-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2011-03-01 US disclosed
US-20100076065-A1 VITAMIN D RECEPTOR MODULATORS LU JIANLIANG 2010-03-25 US disclosed
US-7582775-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-09-01 US disclosed
EP-1687292-B1 VITAMIN D RECEPTOR MODULATORS LILLY CO ELI (US) 2007-08-22 EP disclosed
US-20070149810-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY (US) 2007-06-28 US disclosed
EP-1687292-A2 VITAMIN D RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-08-09 EP disclosed
WO-2005051940-A2 VITAMIN D RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076065-A1 VITAMIN D RECEPTOR MODULATORS VDR, CYP2R1, CYP24A1 ESR1 153/4885ESR2 121/4885HTR7 2609/4885
US-20070149810-A1 Vitamin d receptor modulators VDR, CYP2R1, CYP24A1 ESR1 153/4885ESR2 121/4885HTR7 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.